MAM
CADL icon

Martingale Asset Management’s Candel Therapeutics CADL Stock Holding History

Martingale Asset Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$525K Buy
50,984
+7,075
+16% +$53.4K 0.01% 649
2026
Q1 		$215K Buy
43,909
+6,390
+17% +$34.8K 0.01% 770
2025
Q4 		$212K Buy
+37,519
New +$202K 0.01% 747

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Martingale Asset Management's CADL Position: Q2 2026 in Review

Martingale Asset Management increased its Candel Therapeutics (CADL) stake by 16% in Q2 2026, buying an estimated $53.4K and bringing the position to 50,984 shares worth $525K. The position accounts for 0.01% of the portfolio, ranked #649.

Martingale Asset Management first reported a position in CADL in Q4 2025 and has held it in 3 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Martingale Asset Management held 50,984 shares of Candel Therapeutics worth $525K as of Q2 2026.
  • Martingale Asset Management bought 7,075 Candel Therapeutics shares in Q2 2026, an estimated $53.4K.
  • Candel Therapeutics made up 0.01% of Martingale Asset Management's portfolio in Q2 2026, its #649 holding.
  • Martingale Asset Management first reported a position in Candel Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.